Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis

The Lancet Neurology

Volumn 16, Issue 8, 2017, Pages 601-609

  Byrne, Lauren M ^a   Rodrigues, Filipe B ^a   Blennow, Kaj ^b,c   Durr, Alexandra ^f   Leavitt, Blair R ^d   Roos, Raymund A C ^e   Scahill, Rachael I ^a   Tabrizi, Sarah J ^a   Zetterberg, Henrik ^a,b,c   Langbehn, Douglas ^g   Wild, Edward J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e LEIDEN UNIVERSITY   (Netherlands)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HUNTINGTIN; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG; HTT PROTEIN, HUMAN; NEUROFILAMENT PROTEIN L;

ADULT; AGE; AGED; ARTICLE; BRAIN; BRAIN ATROPHY; BRAIN SIZE; BRAIN VENTRICLE; CAG REPEAT; CAUDATE NUCLEUS; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; DEGENERATIVE DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; FUNCTIONAL STATUS; GENE MUTATION; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOTOR PERFORMANCE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PUTAMEN; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STROOP TEST; SYMBOL DIGIT MODALITIES TEST; UNIFIED HUNTINGTON DISEASE RATING SCALE; WHITE MATTER; YOUNG ADULT; ATROPHY; BLOOD; COGNITIVE DYSFUNCTION; DIAGNOSTIC IMAGING; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; TRINUCLEOTIDE REPEAT;

ADULT; AGED; ATROPHY; BIOMARKERS; BRAIN; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MIDDLE AGED; NEUROFILAMENT PROTEINS; RETROSPECTIVE STUDIES; TRINUCLEOTIDE REPEAT EXPANSION; YOUNG ADULT;

EID: 85020317377     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30124-2     Document Type: Article

References (28)

1. Bates, GP, Dorsey, R, Gusella, JF, et al. Huntington disease. Nat Rev Dis Primers, 1, 2015, 15005.
2. Biglan, KM, Zhang, Y, Long, JD, et al. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci, 5, 2013, 12.
3. Dorsey, ER, Huntington Study Group COHORT Investigators. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS One, 7, 2012, e29522.
4. Ross, CA, Aylward, EH, Wild, EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10 (2014), 204–216.
5. Tabrizi, SJ, Scahill, RI, Owen, G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12 (2013), 637–649.
6. Scahill, RI, Wild, EJ, Tabrizi, SJ, Biomarkers for Huntington's disease: an update. Expert Opinion Med Diagn 6 (2012), 371–375.
7. Byrne, LM, Wild, EJ, Cerebrospinal fluid biomarkers for Huntington's disease. J Huntingtons Dis 5 (2016), 1–13.
8. Wild, EJ, Boggio, R, Langbehn, D, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest 125 (2015), 1979–1986.
9. Rodrigues, FB, Byrne, LM, McColgan, P, et al. Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease. PLoS One, 11, 2016, e0163479.
10. Rodrigues, FB, Byrne, L, McColgan, P, et al. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. J Neurochem 139 (2016), 22–25.
11. Weiss, A, Trager, U, Wild, EJ, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest 122 (2012), 3731–3736.
12. Mochel, F, Benaich, S, Rabier, D, Durr, A, Validation of plasma branched chain amino acids as biomarkers in Huntington disease. Arch Neurol 68 (2011), 265–267.
13. Rosengren, LE, Karlsson, JE, Karlsson, JO, Persson, LI, Wikkelso, C, Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67 (1996), 2013–2018.
14. Landqvist Waldo, M, Frizell Santillo, A, Passant, U, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol, 13, 2013, 54.
15. Constantinescu, R, Romer, M, Oakes, D, Rosengren, L, Kieburtz, K, Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord 15 (2009), 245–248.
16. Vinther-Jensen, T, Bornsen, L, Budtz-Jorgensen, E, et al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm, 3, 2016, e287.
17. Niemelä, V, Landtblom, A-M, Blennow, K, Sundblom, J, Tau or neurofilament light—which is the more suitable biomarker for Huntington's disease?. PLoS One, 12, 2017, e0172762.
18. Rohrer, JD, Woollacott, IO, Dick, KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87 (2016), 1329–1336.
19. Gaiottino, J, Norgren, N, Dobson, R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One, 8, 2013, e75091.
20. Hansson, O, Janelidze, S, Hall, S, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88 (2017), 930–937.
21. Meeter, LH, Dopper, EG, Jiskoot, LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clinical Transl Neurol 3 (2016), 623–636.
22. Steinacker, P, Semler, E, Anderl-Straub, S, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology 88 (2017), 961–969.
23. Lu, CH, Macdonald-Wallis, C, Gray, E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84 (2015), 2247–2257.
24. Rojas, JC, Karydas, A, Bang, J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3 (2016), 216–225.
25. Tabrizi, SJ, Langbehn, DR, Leavitt, BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8 (2009), 791–801.
26. Borowsky, B, Warner, J, Leavitt, BR, et al. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 80 (2013), 1934–1941.
27. Long, JD, Langbehn, DR, Tabrizi, SJ, et al. Validation of a prognostic index for Huntington's disease. Mov Disord 32 (2016), 256–263.
28. Research Councils UK. HD-CSF: studying cerebrospinal fluid to understand key CNS pathobiological targets in Huntington's disease, 2015 http://gtr.rcuk.ac.uk/project/B7BA23DD-DF18-4903-B280-DD00B77D94E9 (accessed May 4, 2017).